BERLIN, and BURLINGTON, Mass., Feb. 28, 2011 /PRNewswire/ —
caprotec bioanalytics GmbH announced today that the European
Patent Office has granted the last of three core patents protecting
its proprietary and revolutionary Capture Compound Mass
Spectrometry (CCMS) technology.
CCMS offers a novel and direct way to investigate small molecule
– protein interactions resulting in a significant functional
reduction of proteome complexity. The core of the CCMS technology
consists of tri-functional small molecules called Capture
Compounds™. These Capture Compounds enable the direct
isolation and identification of selected proteins, including
membrane proteins, out of any complex biological sample.
An important application of the CCMS technology is to profile
small molecule drug – protein interactions in the human proteome to
discover or confirm relevant protein drug targets, the mode of drug
action, and off-target proteins potentially causing adverse side
effects in humans.
The newly granted European Patent No. EP 1583972 titled “Methods
for Identifying Drug Non-targets” covers the use of CCMS technology
for lead optimization and risk assessment of candidate drugs to
make a go or no-go decision to enter the clinical trial phase.
The European Patent No. EP 1485707 titled
“Compounds and Methods for Analyzing the Proteome” covers Capture
Compounds and methods to discover protein biomarkers for diagnostic
applications. European Patent No. EP 1502102 titled “Compounds and
Methods for Analyzing the Proteome” covers an array-based
application of CCMS technology. Equivalent patents have been
issued in many major countries.
“We are pleased about the grant of the last of our three core
CCMS patents in Europe, which protect our proprietary technology
and endorse the uniqueness of this powerful proteome analysis
technology,” states Prof. Dr. Hubert Koester, Founder and Chief
Executive Officer of caprot